Novo Nordisk’s MASH Data Strengthens Semaglutide’s Case as Buyback and Earnings Add Context
Novo Nordisk presents Phase 3 ESSENCE subgroup data for semaglutide in MASH, showing efficacy across underrepresented groups. Revenue…
Novo Nordisk’s Double Play: Digital Authority Meets Clinical Depth as Semaglutide’s Reach Widens
Wegovy tops AI searches; semaglutide shows 63% MASH resolution; oral pill gains momentum. Novo Nordisk faces mixed Q1…
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide,…